Risk factor
High price volatility
Profitability factor
Greatly undervalued vs peers
About
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue
Target Price
The average target price of EMBC is 16 and suggests 49% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell